TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.
Clinical trial NCT00866853 · COMPLETED
Trial details
- NCT number
- NCT00866853
- Sponsor
- Tibotec Pharmaceuticals, Ireland
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-03-01
- Primary completion
- 2009-07-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.